# ARS Pharmaceuticals, Inc. (SPRY) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from ARS Pharmaceuticals, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/SPRY/mda/fy2025/): filed 2026-03-09; accession 0001193125-26-097478 (https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/spry-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/SPRY/mda/fy2024/): filed 2025-03-20; accession 0000950170-25-042320 (https://www.sec.gov/Archives/edgar/data/1671858/000095017025042320/spry-20241231.htm)
- [FY 2023 MD&A](/company/SPRY/mda/fy2023/): filed 2024-03-21; accession 0000950170-24-034689 (https://www.sec.gov/Archives/edgar/data/1671858/000095017024034689/spry-20231231.htm)
- [FY 2022 MD&A](/company/SPRY/mda/fy2022/): filed 2023-03-23; accession 0000950170-23-009491 (https://www.sec.gov/Archives/edgar/data/1671858/000095017023009491/spry-20221231.htm)
- [FY 2021 MD&A](/company/SPRY/mda/fy2021/): filed 2022-03-31; accession 0000950170-22-005202 (https://www.sec.gov/Archives/edgar/data/1671858/000095017022005202/sbtx-20211231.htm)

Back to /company/SPRY/